The Beauty Health Co
SKINBuild a strategy around SKIN
The Beauty Health Co AI Insights
Informational only. Not investment advice.Snapshot
- Debt/equity of 5.8x with 379M debt vs 66M equity; tangible book value is -99M. Interest expense (15.4M TTM) exceeds operating income (-28M).[Debt to Equity]
- Gross margin 64.8% TTM vs industry median 46.2% - premium pricing power intact despite -10.3% revenue decline.[Gross Margin TTM]
- FCF of 34M TTM on -12M net income; cash conversion masks operating losses through working capital management.[Free Cash Flow TTM]
Watch Triggers
- Total Revenue 1yr Growth: Turns positive or decline accelerates beyond -15% — Revenue trajectory determines if debt is serviceable or if capital raise becomes urgent
- Free Cash Flow TTM: Falls below 20M or turns negative — FCF is only buffer against operating losses; loss here accelerates liquidity crisis
- Interest Expense TTM: Rises above 18M on refinancing — Higher rates on debt rollover could push company toward distress
Bull Case
Gross margin 64.8% (vs 46% median) with 34M FCF proves core business model works; 219M cash buys time for turnaround.
P/S 0.59x vs industry 1.0x median; EV/Revenue 1.1x on 302M revenue implies deep value if operations stabilize.
Bear Case
Revenue declining -10.3% 1Y and -7.3% 3Y CAGR while carrying 379M debt at 5.8x equity - structural decline with leverage.
Goodwill 126M is 193% of equity (66M); any impairment triggers covenant issues or wipes equity entirely.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage SKIN's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Debt refinancing or equity raise likely within 12-18 months as 374M long-term debt overwhelms 66M equity
- Interest expense 15.4M vs operating income -28M TTM
- Tangible book value -99M limits borrowing capacity
- 219M cash provides runway but not solution
Valuation Context
Caveats
Public Strategies Rankings
See how The Beauty Health Co ranks across different investment strategies.
Leverage SKIN's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
SKIN Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$121.79M | — | ||
$267.87M | — | ||
0.00 | — | ||
$300.79M | -10.0% | — | |
$-0.16 | — | ||
-6.92% | +13.4% | — | |
-3.16% | +5.5% | — | |
$32.32M | +246.1% | — | |
-16.9% | +35.5% | — | |
Beta 5Y (Monthly) | unknown | — |
SKIN Dividend History
SKIN Stock Splits
SKIN SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/12/26 | 12/31/25 | Unknown | |
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
03/12/25 | 12/31/24 | 10-K | |
11/12/24 | 09/30/24 | 10-Q | |
08/08/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
03/12/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/09/23 | 06/30/23 | 10-Q | |
05/10/23 | 03/31/23 | 10-Q | |
03/01/23 | 12/31/22 | 10-K | |
11/09/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/10/22 | 03/31/22 | 10-Q | |
03/01/22 | 12/31/21 | 10-K | |
11/12/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
07/19/21 | 03/31/21 | NT 10-Q | |
07/19/21 | 12/31/20 | PREM14A | |
11/12/21 | 09/30/20 | 10-Q | |
08/13/21 | 06/30/20 | 10-Q | |
07/19/21 | 03/31/20 | Quarterly | -- |